Home▸Shingles (Herpes Zoster) & Mononucleosis▸Postherpetic Neuralgia Pain Simulator

🔥 Postherpetic Neuralgia Pain Simulator

A simulation of postherpetic neuralgia pain following herpes zoster, depending on the patient's age, severity of rash, and time to antiviral therapy initiation.

Shingles (Herpes Zoster) & Mononucleosis2DModerate60 FPS
postherpetic-neuralgia-pain-simulator ↗ Open standalone

Acute Rash-Associated Pain in Herpes Zoster

Placeholder: acute dermatomal pain accompanies the shingles rash.

  • Days 1–5: Pain onset (Placeholder timing note)
  • 5–8/10: Typical VAS score (Placeholder severity note)
  • 1–3: Dermatomes affected (Placeholder distribution note)
  • 2–4 wks: Rash duration (Placeholder duration note)

Rash and acute neuritis

Placeholder: reactivated virus inflames the nerve and skin together.

Sensory Nerve Fiber Injury Along the Dermatome

Placeholder: viral replication damages sensory axons and ganglia.

  • Dorsal root: Ganglion involved (Placeholder location note)
  • A-delta, C: Fiber types hit (Placeholder fiber note)
  • Age-linked: Damage severity (Placeholder risk note)
  • Weeks–months: Recovery window (Placeholder recovery note)

Axonal injury and demyelination

Placeholder: older patients show greater nerve fiber loss.

Aberrant Pain Signal Generation and Central Sensitization

Placeholder: injured fibers generate spontaneous ectopic firing.

  • Elevated: Ectopic firing (Placeholder mechanism note)
  • Common: Central sensitization (Placeholder spinal note)
  • ~30%: Allodynia rate (Placeholder symptom note)
  • Irregular: Signal pattern (Placeholder pattern note)

Ectopic firing and spinal amplification

Placeholder: damaged fibers misfire and amplify pain centrally.

Effect of Antiviral Treatment Timing on Pain Outcomes

Placeholder: earlier antiviral therapy reduces nerve damage extent.

  • <72 hrs: Ideal start window (Placeholder timing note)
  • Worse pain: Delayed start effect (Placeholder outcome note)
  • Acyclovir class: Common antivirals (Placeholder drug note)
  • Moderate: Benefit magnitude (Placeholder effect note)

Treatment window and nerve protection

Placeholder: fast antiviral start limits viral nerve injury.

Chronic Pain Trajectory Over Months — Resolution or Persistence

Placeholder: pain either fades over months or persists as PHN.

  • ~10–20%: PHN at 3 months (Placeholder prevalence note)
  • ~5–10%: PHN at 1 year (Placeholder prevalence note)
  • Much higher: Older age risk (Placeholder risk note)
  • 1–12 months: Typical resolution (Placeholder timeline note)

Long-term pain resolution patterns

Placeholder: trajectory depends on age, severity, and treatment timing.

Placeholder: older patients with delayed treatment face longer chronic pain.
⚙ Under the hood

A simulation of postherpetic neuralgia pain following herpes zoster, depending on the patient's age, severity of rash, and time to antiviral therapy initiation.

CanvasBiomedicine

2D · HTML5 Canvas 2D · 60 FPS target · runs fully client-side, no install

What did you find?

Add reproduction steps (optional)